Abstract:Introduction Atherosclerotic cardiovascular disease is the leading cause of death in the United States. Intimal macrophages are determinant cells in the atherosclerotic lesion formation by facilitating cholesterol accumulation and increasing the inflammatory response in blood vessel walls. T0901317 can prevent and dramatically regress atherosclerosis by increasing cholesterol efflux and inhibiting inflammatory response via activating macrophage liver X receptors (LXR) . However its side effects including hypertriglyceridemia and hepatic steatosis hinder its application in clinics. We have successfully made T0901317 encapsulated nanovesicles (Tnano) and ligand‐incorporated Tnano (LTnano). Nanovesicles without T0901317 is Vnano, ligand Vnano is LVnano. This target ligand has a high binding affinity to macrophage scavenger receptor CD36. The object of the project is to investigate the anti‐atherogenic effect of LTnano in macrophages. Methods We used THP‐1 derived macrophages in this study. CD36 siRNA and Lipofectamine® RNAiMAX Transfection Reagent were used to knock down the CD36 in these macrophages. Scrambled SiRNA were used as a control. Fluorescence 1‐Oleoyl‐2‐[12‐[(7‐nitro‐2‐1,3‐benzoxadiazol‐4‐yl)amino]dodecanoyl]‐sn‐Glycero‐3‐Phosphocholine (NBD) were used to label all nanovesicles. THP‐1 derived macrophages and CD36 knockdown macrophages were treated with NBD‐labeled nanovesicles at 37 °C for 2 hours. After washing, cell nuclei were stained with 4′,6‐diamidino‐2‐phenylindole dihydrochloride (DAPI). Macrophage binding and uptake of nanovesicles were observed under an EVOS® fluorescence microscope. To investigate the cholesterol lowering effect, THP‐1 derived macrophages were treated with Tnano, LTnano, free T0901317 at 1μM and controls (Vnano, LVnano, PBS). Total cholesterol and free cholesterol were measured using a HPLC method. Cholesterol ester was calculated as the difference between total and free cholesterol. Gene expression of scavenger receptors and some cytokines were measured using real time PCR. Results LTnano had a higher binding affinity to macrophages than Tnano. CD36 knockdown diminished LTnano binding to and uptake by macrophages. LTnano also decreased macrophage total and free cholesterol content compare to free T0901317 or Tnano. LTnano increased the mRNA levels of ATP Binding Cassette Subfamily A Member 1 and ATP‐binding cassette sub‐family G member 1 . Expression of LXR, tumor necrosis factor alpha, monocyte chemoattractant protein‐1, and interleukin 6, macrophage scavenger receptor 1, scavenger receptor class B member 1, CD36 will be determined. Conclusions LTnano targeted macrophages via their CD36 binding sites. LTnano decreased macrophage total and free cholesterol content, which correlated with increased expression of ABCA1 and ABCG1. Additional anti‐atherogenic mechanisms are under investigation. Support or Funding Information Grant Funding Source: NIH 1R15AT007013‐01

Targeting Macrophage Liver X Receptors by Hydrogel‐encapsulated T0901317 Reduces Atherosclerosis Without Effect on Hepatic Lipogenesis

Glycine-β-muricholic acid antagonizes the intestinal farnesoid X receptor-ceramide axis and ameliorates NASH in mice

Encapsulation of LXR ligand by D-Nap-GFFY hydrogel enhances anti-tumorigenic actions of LXR and removes LXR-induced lipogenesis

Anti‐atherogenic Effect of T0901317 Nanovesicles in THP‐1 Derived Macrophages

Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review

Targeted Nanotherapeutics Encapsulating Liver X Receptor Agonist GW3965 Enhance Antiatherogenic Effects Without Adverse Effects on Hepatic Lipid Metabolism in Ldlr−/− Mice

LXR Agonist T0901317′s Hepatic Impact Overrules Its Atheroprotective Action in Macrophages, Driving Early Atherogenesis in Chow-Diet-Fed Male Apolipoprotein E Knockout Mice

The Effect of T0901317 on ATP-binding Cassette Transporter A1 and Niemann-Pick Type C1 in Apoe-/- Mice.

Nanoparticles Containing a Liver X Receptor Agonist Inhibit Inflammation and Atherosclerosis

Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression.

Abstract 13: Development of Functionalized Nanoparticle Platform for Reducing Atherosclerosis

Combination of mangiferin and T0901317 targeting autophagy promotes cholesterol efflux from macrophage foam cell in atherosclerosis

Development of Mannose Functionalized Dendrimeric Nanoparticles for Targeted Delivery to Macrophages: Use of This Platform to Modulate Atherosclerosis

Impaired adipose expansion caused by liver X receptor activation is associated with insulin resistance in mice fed a high-fat diet.

Regulation Of Insulin Resistance And Adiponectin Signaling In Adipose Tissue By Liver X Receptor Activation Highlights A Cross-Talk With Ppar Gamma

Synthetic High-Density Lipoproteins Delivering Liver X Receptor Agonist Prevent Atherogenesis by Enhancing Reverse Cholesterol Transport.

Discovery of Tissue Selective Liver X Receptor Agonists for the Treatment of Atherosclerosis Without Causing Hepatic Lipogenesis.

cRGD-platelet@MnO/MSN@PPARα/LXRα Nanoparticles Improve Atherosclerosis in Rats by Inhibiting Inflammation and Reducing Blood Lipid

Targeted Delivery of Liver X Receptor Agonist to Inhibit Neointimal Hyperplasia by Differentially Regulating Cell Behaviors.

Inflammatory Endothelium-Targeted and Cathepsin Responsive Nanoparticles Are Effective Against Atherosclerosis

FXR activation reduces the formation of macrophage foam cells and atherosclerotic plaque, possibly by down regulating hepatic lipase in macrophages